ArticleTropical medicine & international health : TM & IH2026
Recombinant LPG3 Protein From Leishmania chagasi as an Antigen for the Diagnosis of Canine Visceral Leishmaniasis.
Article in Tropical medicine & international health : TM & IH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Visceral leishmaniasis (VL) is a human neglected tropical disease in which dogs participate as reservoirs of the etiological agent Leishmania chagasi. The identification of infected dogs is important to the control of VL, and recombinant proteins are strong antigen candidates for canine visceral leishmaniasis (CVL) serodiagnosis. In this work, we evaluated the enzyme-linked immunosorbent assay (ELISA) using the L. chagasi LPG3 recombinant protein (rLPG3) as an antigen for the CVL diagnosis. The tests were performed on 242 serum samples and showed a remarkable 95.71% sensitivity and 87.50% specificity, with cross-reactivity observed in some samples positive for Ehrlichia canis and Trypanosoma cruzi. The performance of the rLPG3-ELISA test was similar to the performance of IFI-CVL and IFI-CVL plus ELISA-CVL Bio-Manguinhos tests, widely used in the diagnosis of CVL in Brazil, and presented better sensitivity results compared to those obtained in rapid tests available for CVL using other antigenic proteins. Further refinement is necessary to minimize the cross-reactivity and enhance the specificity of the test. Studies to discriminate cross-reactive epitopes of rLPG3, particularly those shared with E. canis protein sequences, may help improve diagnostic accuracy by excluding these epitopes from the detection reaction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.